Promedior makes a 'breakthrough' with PhIII IPF drug; NASH focused NGM Biopharma sets terms for IPO; bluebird bio says LentiGlobin is still under EU review, despite conflicting report
→ Closing in on 3 years since Bristol-Myers $BMY struck an option deal to buy Promedior for up to $1.25 billion, the biotech says that it’s gained breakthrough therapy status for its star fibrosis drug PRM-151, now in a Phase III program for IPF. Promedior says that regulators based their decision on positive Phase II results, which set up the newly launched late-stage program. Researchers will be using forced vital capacity as a primary endpoint and six-minute walk distance as the key secondary endpoint.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
